| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 16.423 | 14.570 | 14.712 | 21.837 | 204.383 | 197.674 | 130.372 | 93.103 | 93.888 | 45.378 |
| Total Income - EUR | 22.353 | 20.440 | 20.482 | 27.501 | 209.939 | 203.125 | 134.354 | 93.104 | 93.891 | 45.443 |
| Total Expenses - EUR | 21.652 | 19.742 | 20.333 | 25.083 | 203.489 | 196.454 | 128.332 | 90.402 | 90.404 | 47.785 |
| Gross Profit/Loss - EUR | 702 | 697 | 149 | 2.419 | 6.450 | 6.671 | 6.021 | 2.702 | 3.487 | -2.342 |
| Net Profit/Loss - EUR | 209 | 397 | 2 | 2.200 | 4.407 | 4.817 | 4.874 | 1.893 | 2.659 | -2.342 |
| Employees | 2 | 1 | 2 | 3 | 8 | 20 | 14 | 8 | 5 | 3 |
Check the financial reports for the company - Anflabio S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 48.715 | 39.833 | 30.915 | 22.255 | 13.888 | 5.839 | 0 | 3.949 | 3.519 | 1.730 |
| Current Assets | 28.054 | 13.058 | 18.885 | 34.082 | 115.356 | 67.009 | 56.898 | 26.266 | 38.388 | 19.829 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 21.035 | 12.506 | 15.409 | 27.534 | 81.488 | 38.393 | 54.655 | 24.520 | 28.010 | 13.600 |
| Cash | 7.019 | 552 | 3.476 | 6.547 | 33.868 | 28.616 | 2.243 | 1.746 | 10.378 | 6.229 |
| Shareholders Funds | -3.218 | -2.788 | -2.739 | -489 | 3.929 | 8.672 | 13.353 | 15.288 | 17.901 | 15.459 |
| Social Capital | 225 | 223 | 219 | 215 | 213 | 209 | 204 | 205 | 204 | 203 |
| Debts | 45.905 | 55.680 | 30.916 | 41.264 | 115.610 | 60.106 | 43.544 | 14.926 | 24.092 | 6.100 |
| Income in Advance | 34.083 | 27.865 | 21.623 | 15.561 | 9.705 | 4.071 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4221 - 4221" | |||||||||
| CAEN Financial Year |
4221
|
|||||||||
Comments - Anflabio S.r.l.